A Video on Bone Metastases & Zometa

I recently made a video with Dr. James Mckiernan of Columbia Presbyterian Hospital in New York City on the use of Zometa (zoledronic acid) to combat bone metastases in advanced prostate cancer that is castrate resistant. Novartis Oncology, the makers of Zometa, sponsored the video and it was produced on the Wego Health web page. [...]

Key Information About the FDA Approval of Zytiga (Abiraterone Acetate)

The FDA approval of Zytiga (abiraterone acetate) for men with advanced prostate cancer defines the men who qualify to receive the drug. To qualify you must have advanced prostate cancer and meet all of the three criteria below: 1- Men who are metastatic. 2- Men who failed hormone therapy also known as castrate resistant or [...]

FDA Approves Zytiga (abiraterone acetate) for Late-Stage Prostate Cancer

The long awaited FDA approval of Zytiga (abiraterone acetate), a once-daily oral agent, for the treatment of castration-resistant, metastatic prostate cancer following docetaxel chemotherapy has happened! Malecare celebrates this approval as it celebrates the significant numbers of new drug approvals we have had over the last year and one half. The approval of Zytiga represents [...]

Should Men on ADT Take Calcium and Vitamin D Supplementation?

As usual with prostate cancer there is no general agreement about whether or not men who are on a hormone blockade (ADT) to treat prostate cancer should be taking calcium and vitamin D supplements, however there does seem to be some consensus that they should. Given that there are geographic and seasonal variations in vitamin [...]

Minorities, Especially Blacks Are More Willing to Spend All for Cancer Care

An AP medical writer, Mike Stobb, wrote an interesting and unusual article about a survey that was conducted asking if people would be willing to spend everything they have on aggressive treatments that might prolong their life. The survey concluded that blacks and other minorities with cancer are more likely than whites to say they [...]

Go to Top